Phibro Animal Health (NASDAQ:PAHC) Updates FY 2025 Earnings Guidance

Phibro Animal Health (NASDAQ:PAHC) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.870-2.010 for the period, compared to the consensus EPS estimate of 1.710. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.

Phibro Animal Health Stock Up 1.6 %

PAHC stock traded up $0.35 during trading on Wednesday, hitting $22.37. 149,110 shares of the stock traded hands, compared to its average volume of 141,187. Phibro Animal Health has a 1 year low of $10.03 and a 1 year high of $25.98. The firm’s 50 day moving average is $21.89 and its two-hundred day moving average is $21.60. The stock has a market cap of $905.99 million, a price-to-earnings ratio of 52.02, a price-to-earnings-growth ratio of 0.56 and a beta of 0.52. The company has a debt-to-equity ratio of 1.81, a current ratio of 3.23 and a quick ratio of 1.69.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.40 by $0.14. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%. On average, sell-side analysts anticipate that Phibro Animal Health will post 1.62 EPS for the current year.

Phibro Animal Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 26th. Stockholders of record on Wednesday, March 5th will be given a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 2.15%. The ex-dividend date is Wednesday, March 5th. Phibro Animal Health’s payout ratio is currently 111.63%.

Analyst Ratings Changes

A number of research analysts recently weighed in on PAHC shares. StockNews.com raised shares of Phibro Animal Health from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 29th. Barclays boosted their target price on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a research note on Tuesday, November 12th. Finally, Morgan Stanley upped their price target on shares of Phibro Animal Health from $20.00 to $25.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $20.50.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.